Alnylam announces 3-month extension of review period for new drug application for vutrisiran

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced that the u.s. food and drug administration (fda) has extended the review timeline of the new drug application (nda) for vutrisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. alnylam r
ALNY Ratings Summary
ALNY Quant Ranking